Ultrasound+, powered by FDA-cleared Koios DS software, provides real-time decision support to assist radiologists in detecting breast and thyroid cancers.
SimonMed Imaging announced the launch of Ultrasound+, an AI-enabled ultrasound program powered by US Food and Drug Administration (FDA)-cleared software, Koios DS, to assist with breast and thyroid cancer detection.
Ultrasound+ uses advanced algorithms to analyze breast and thyroid ultrasound images in real time, providing classifications based on millions of data points. Acting as a second read for radiologists, the program is trained to identify subtle patterns linked to breast and thyroid cancers that may not always be visible to the human eye.
SimonMed partnered with Koios Medical, developer of FDA-cleared AI tools that provide real-time decision support during ultrasound exams. Through this collaboration, SimonMed has integrated AI technology to improve the clarity, accuracy, and consistency of ultrasound reads—now available system-wide across all locations nationwide.
“By making Ultrasound+ available at every location offering ultrasound exams, every patient who comes to SimonMed for a breast or thyroid ultrasound now benefits from AI-enhanced imaging,” says Dr John Simon, CEO and founder of SimonMed Imaging, in a release. “This reimbursable-eligible technology helps us detect cancers earlier, reduce unnecessary procedures, and ultimately improve outcomes for patients everywhere.”
Potential benefits include:
- Earlier detection: The AI tool assists radiologists in identifying subtle signs of breast and thyroid cancer.
- Fewer follow-up procedures: The technology may help reduce unnecessary biopsies and additional imaging.
- Improved consistency: AI analysis aims to enhance the accuracy and uniformity of ultrasound interpretations.
“Ultrasound+ builds on the success of our Mammogram+ and AI-enhanced mammography programs, further cementing SimonMed as a leader in women’s health,” says Dr Sean Raj, chief medical officer and chief innovation officer at SimonMed Imaging, ina release. “We are committed to creating the most comprehensive, technology-driven women’s health program in the country—one that ensures earlier detection, more accurate diagnoses, and better outcomes for patients.”
The AI-enhanced, reimbursement-eligible technology is available for breast and thyroid imaging at all locations providing ultrasounds.
ID 20798663 © Alexander Raths | Dreamstime.com
